- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
CytomX Therapeutics Inc (CTMX)
CytomX Therapeutics Inc stock price live, this page displays NASDAQ CTMX stock exchange data. View the CTMX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the CytomX Therapeutics Inc real time stock price chart below.
What Is the CytomX Therapeutics Inc Stock Price Today?
The CytomX Therapeutics Inc stock price today is 2.250.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock symbol for CytomX Therapeutics Inc is ""CTMX.""
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is CytomX Therapeutics Inc a Good Stock to Buy?
Determining whether CytomX Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTMX quote. (ISIN: US23284F1057)
What Is the CytomX Therapeutics Inc Stock Price Today?
The CytomX Therapeutics Inc stock price today is 2.250.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock symbol for CytomX Therapeutics Inc is ""CTMX.""
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is CytomX Therapeutics Inc a Good Stock to Buy?
Determining whether CytomX Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CTMX quote. (ISIN: US23284F1057)
2.250
-0.140(-5.86%)
Closed·
Fair Value
An estimate of a CytomX Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.185
2.370
52 wk Range
0.400
3.095
CTMX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 9 days
More Info
Fair Value
An estimate of a CytomX Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1852.370
52 wk Range
0.4003.095
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CTMX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a CytomX Therapeutics Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
5.500
Upside
+144.44%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K CytomX Therapeutics Inc For: 13 June
- Investing.com
- Form 8K CytomX Therapeutics Inc For: 13 June
- Investing.com
- CytomX stock soars to 52-week high, hits $2.66
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
CytomX Therapeutics Inc Company Profile
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company’s development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
CytomX Therapeutics Inc SWOT Analysis
Pipeline Progress | Explore CytomX's innovative cancer therapies, including EGFRxCD3 for solid tumors and EpCAM ADC for colorectal cancer, with pivotal data expected by 2025 |
Financial Fortification | Learn how CytomX's strategic workforce reduction extends cash runway to Q2 2026, balancing financial prudence with development needs |
Collaborative Potential | Delve into CytomX's partnership with Amgen, offering resource synergies and market credibility, with potential opt-in decision as a major catalyst |
Market Positioning | Analysts set an average price target of $3.50, reflecting optimism in CytomX's probody platform amid the competitive oncology landscape |
CytomX Therapeutics Inc Earnings Call Summary for Q1/2025
- CytomX Therapeutics reports Q1 2025 EPS of $0.27, beating $0.06 forecast; revenue of $50.92M surpasses $29.7M expectation
- Stock surges 117.58% in premarket trading to $2.02; P/E ratio of 1.77 indicates attractive valuation
- Company secures $100M financing to support CX-2051 development for colorectal cancer; Phase II study planned for H1 2026
- Management aims to establish CX-2051 as new standard of care in late-line CRC, with potential for earlier treatment lines
- Positive outlook tempered by potential regulatory hurdles, competition, and clinical trial complexities
Last Updated: 12/05/2025, 14:14
Read Full TranscriptCompare CTMX to Peers and Sector
Metrics to compare | CTMX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTMXPeersSector | |
|---|---|---|---|---|
P/E Ratio | 8.5x | −1.5x | −0.5x | |
PEG Ratio | 0.07 | 0.00 | 0.00 | |
Price/Book | 14.2x | 0.8x | 2.6x | |
Price / LTM Sales | 2.4x | 33.5x | 3.2x | |
Upside (Analyst Target) | 111.9% | 187.3% | 41.2% | |
Fair Value Upside | Unlock | 44.9% | 6.2% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 5.500
(+144.44% Upside)
Earnings
Latest Release
May 12, 2025
EPS / Forecast
0.27 / 0.06
Revenue / Forecast
50.92M / 29.70M
People Also Watch
FAQ
What Stock Exchange Does CytomX Therapeutics Inc Trade On?
CytomX Therapeutics Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for CytomX Therapeutics Inc?
The stock symbol for CytomX Therapeutics Inc is "CTMX."
What Is the CytomX Therapeutics Inc Market Cap?
As of today, CytomX Therapeutics Inc market cap is 355.26M.
What Is CytomX Therapeutics Inc's Earnings Per Share (TTM)?
The CytomX Therapeutics Inc EPS (TTM) is 0.49.
When Is the Next CytomX Therapeutics Inc Earnings Date?
CytomX Therapeutics Inc will release its next earnings report on 06 Aug 2025.
From a Technical Analysis Perspective, Is CTMX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has CytomX Therapeutics Inc Stock Split?
CytomX Therapeutics Inc has split 0 times.
How Many Employees Does CytomX Therapeutics Inc Have?
CytomX Therapeutics Inc has 120 employees.
What is the current trading status of CytomX Therapeutics Inc (CTMX)?
As of 29 Jul 2025, CytomX Therapeutics Inc (CTMX) is trading at a price of 2.25, with a previous close of 2.39. The stock has fluctuated within a day range of 2.19 to 2.37, while its 52-week range spans from 0.40 to 3.10.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.